lunedì, 23 novembre 2020
30 Agosto 2018

Blinatumomab Approved in Europe for Pediatric ALL

August 29, 2018 – The European Commission (EC) has approved blinatumomab for the treatment of pediatric patients with Philadelphia chromosome–negative (Ph-), CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in relapse after receiving at least 2 prior therapies or in relapse after receiving prior allogeneic hematopoietic stem cell transplantation (HSCT). The approval of the anti-CD19 immunotherapy was based on data from a … (leggi tutto)